485PD - Genetic variation in immune genes and prognosis of locoregionally advanced nasopharyngeal carcinoma

Date 21 December 2015
Event ESMO Asia 2015 Congress
Session Basic Science, biomarkers, new diagnostics and translational research
Topics Immunotherapy
Head and Neck Cancers
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Huai Liu
Citation Annals of Oncology (2015) 26 (suppl_9): 148-152. 10.1093/annonc/mdv533
Authors H. Liu1, Y. Li1, Y. Wen2, M. Zhang3, Q. Chen4, Y. Luo1, H. Wang1, H. Wang3, H. Mai4
  • 1Department Of Radiotherapy, Hunan Provincial Tumor Hospital, 410013 - Changsha/CN
  • 2Department Of Radiotherapy, Guangzhou Medicine College Affiliated Cancer Hospital, Guangzhou/CN
  • 3Key Laboratory, Cancer Centre Sun Yat-Sen University, 510060 - Guangzhou/CN
  • 4Department Of Nasopharyngeal Carcinoma, Cancer Centre Sun Yat-Sen University, 510060 - Guangzhou/CN



To explore the association between immune gene polymorphisms and prognosis in patients with locoregionally advanced nasopharyngeal carcinoma (LANPC).


Forty-three immune genes and 107 potential functional single nucleotide polymorphisms (SNPs) were chosed using the candidate gene approach. The primary endpoint was overall survival (OS). Genotypes were detected by SNP microarray in the training cohort which included 312 LANPC patients. SNPs which were related with OS in the training cohort would be genotyped in the validation cohort (prospectively recruited 420 LANPC patients) by polymerase chain reaction-ligase detection reaction method. The Kaplan–Meier method was used to estimate OS curves, and the log-rank test was used to compare survival curves. Cox proportional hazard model was applied for multivariate analyses. The Hardy–Weinberg equilibrium was determined for each SNP using the χ2 test. In order to control the false discovery rate (FDR), the Q value was calculated by R software, with the significance level of 0.10.


Sixteen SNPs from 13 immune genes were associated with OS in the trainning cohort (Ptrend ≤0.15). Among them, IL1A rs20540 (3.6%) and CD5 rs2229177 (4.4%) were excluded from further analysis because of their minor allele frequency lower than 0.05. Results from the validation cohort showed that IL16 rs61752774 (Ptrend =0.001, Q =0.012), rs8031107 (Ptrend =0.008, Q =0.033) and CCR2 rs1799864(Ptrend =0.006, Q =0.033)were significantly related with OS. Multivariate analysis showed these three SNPs were independent prognostic factors for OS, and patients carried rs61752774 TT (CC/CT vs. TT: HR =3.146, 95% CI 1.128-8.774, P =0.029), rs8031107 AA (AG/GG vs. AA: HR =2.163, 95% CI 1.274-3.672, P =0.004) or rs1799864 GG (AA/AG vs. GG: HR =2.509, 95% CI 1.296-4.856, P =0.006) had significantly increased death risk. We then calculated individual SNPs score according to the number of risk genotyps they carried. And we found that the SNPs score was an independent prognostic factor for OS, and ROC curve showed that the SNP score was better in predicting survival than clinical stage.


IL-16 rs61752774, IL-16 rs8031107 and CCR2 rs1799864 were novel independent prognostic factors in patients with LANPC.

Clinical trial identification


All authors have declared no conflicts of interest.